Abu Dhabi introduces a revolutionary gene therapy for hemoglobinopathies, utilizing CRISPR-Cas9 technology. Explore how this ...

Abu Dhabi successfully completes its first gene therapy for genetic blood disorders, revolutionizing treatment approaches for ...

The US FDA has approved the drug Mitapivat, marketed as Aqvesme, as the very first oral therapy for anemia in adults with ...

CRISPR/Cas9 gene-editing therapy is a groundbreaking technology that enables highly precise modification of disease-causing ...

The US FDA has greenlit Mitapivat, the first oral treatment for anaemia in adults with thalassemia, marking a significant advancement in thalassemia care.

Aurora Therapeutics, cofounded by Nobel Prize–winning scientist Jennifer Doudna, plans to use gene editing and a new FDA ...

Kavita Mehta is pinning her hopes on 2026 for a cure to a major blood disorder, following a breakthrough gene-editing ...

CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for ...

As CRISPR moves from lab success to real-world medicine, 2026 will test whether these revolutionary gene-editing therapies ...

Insights from analysts' 12-month price targets are revealed, presenting an average target of $496.45, a high estimate of $564.00, and a low estimate of $414.00. Witnessing a positive shift, the ...

Parabilis Medicines raised $305 million in a Series F round led by RA Capital, Fidelity and Janus Henderson, with crossover ...